BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy derived from plasmacytoid dendritic cell precursors with skin, lymph node, blood, central nervous system (CNS), and bone marrow involvement.8 While BPDCN is currently considered a unique myeloid neoplasm, it had previously been classified as a subset of acute myeloid lymphoma (AML).9
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy derived from plasmacytoid dendritic cell precursors with skin, lymph node, blood, central nervous system (CNS), and bone marrow involvement.8 While BPDCN is currently considered a unique myeloid neoplasm, it had previously been classified as a subset of acute myeloid lymphoma (AML).9
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy derived from plasmacytoid dendritic cell precursors with skin, lymph node, blood, central nervous system (CNS), and bone marrow involvement.8 While BPDCN is currently considered a unique myeloid neoplasm, it had previously been classified as a subset of acute myeloid lymphoma (AML).9
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy derived from plasmacytoid dendritic cell precursors with skin, lymph node, blood, central nervous system (CNS), and bone marrow involvement.8 While BPDCN is currently considered a unique myeloid neoplasm, it had previously been classified as a subset of acute myeloid lymphoma (AML).9
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy derived from plasmacytoid dendritic cell precursors with skin, lymph node, blood, central nervous system (CNS), and bone marrow involvement.8 While BPDCN is currently considered a unique myeloid neoplasm, it had previously been classified as a subset of acute myeloid lymphoma (AML).9
- Pemmaraju N, et al. Blood. 2023;141(6):567-578.
- Bueno C, et al. Haematologica. 2004;89(1):58-69.
- Laribi K, et al. Blood Adv. 2020;4(19):4838-4848.
- Sullivan JM, Rizzieri DA. Hematology Am Soc Hematol Educ Program. 2016;2016(1):16-23.
- Murthy GSG, et al. Leuk Res. 2018;73:21-23.
- Pagano L, et al. Haematologica.
- Poret E et al. Blood. 2015;126(23).
- Cascio MJ, et al. Precision Molecular Pathology of Myeloid Neoplasm.2017: 353-367.
- Vardiman JW, et al. Blood. 2009;114(5):937-951.
- Renosi F, et al. Cancers (Basel). 2022;14(17):4132.
- Griffin GK, et al. Nature. 2023;618(7966):834-841.
- Togami K, et al. Cancer Discov. 2022;12(2):522-541.
- Montero J, et al. Cancer Discov. 2017;7(2):156-164.
- Sapienza MR, et al. Leukemia. 2014;28(8):1606–1616.
- Jordan CT, et al. Leukemia. 2000;14(10):1777-1784.
- Wang W, et al. Haematologica. 2021;106(4):1047-1055.
- Khoury JD, et al. Leukemia. 2022;36(7):1703-1719.
- Julia F, et al. Br J Dermatol. 2013;169(3):579-586.
- Laribi K, et al. Blood Adv. 2020;4(19):4838-4848.
- Han L, et al. Cytometry A 2015;87:346-56.
- Pemmaraju N, Deconinck E, Mehta P, et al: Recent advances in the biology and CD123-directed treatment of blastic plasmacytoid dendritic cell neoplasm. Clin Lymphoma Myeloma Leuk 24:e130-e137, 2024.
